Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial For Psoriasis

February 2nd, 2009 · No Comments
1

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) have search out admiration to get going Phase 2 clinical carrying out test of PH-10, the company’s topical linctus all for dermatology, for the use of psoriasis.

OmniBank(R) is a copy trademark of Lexicon Genetics Incorporated.

In the study, PH-10 will be applied twice over weekly for competent to twelve weeks to respectively subject’s psoriatic plaque area. Response will be observed in this treatment point, and for one month after the come to an end of this extent. Response will be position using the Psoriasis Severity Index (PSI) and an investigator’s clinical survey of Plaque Response. Changes in pruritus (itching), time-to-response (TTR) and preliminary assessment of immovability of answer will also be assess, along with all-embracing refuge television. The study will be conduct at the Mount Sinai School of Medicine in New York City. Further particulars of the study will be accessible in the practical projected by the snappy of the clinical torment registry position, “Building on the grades from our Phase 1 program, which look at safety and preliminary efficacy of several formulations of PH-10, we be thrilled to begin this Phase 2 study in psoriasis,” said Craig Dees, PhD, Chief Executive Officer of Provectus. “In insert to this study, we be hopeful of to shortly begin clinical study of PH-10 for atopic dermatitis (eczema), and are continuing pre-clinical study of PH-10 for treatment of contagious disease of the rawhide, firm on antibiotic watertight Staphylococcus aureus (MRSA), which is a rapidly increasing basic population form care.” Dees lingering: “Topical PH-10 may be advantageous in psoriasis, eczema, and other suggestion in dermatology that are largely underserved souk characterized by dear products that normally step by a numeral of a curious deal undesirable side-effects, plus syndicate or systemic infectivity and in quite a lot of cases can proceed in cancer. We are happy that PH-10 can rearrange the opportunity available to a huge digit of these patients.” About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specialize in sprouting oncology and dermatology therapy that are safer, more earth-shattering and less significant number transmit than received therapies. Provectus is at the moment conduct clinical trial of their proprietary drugs PV-10 by means of a psychotherapy for melanoma and breast cancer, and PH-10 as a topical treatment for severe psoriasis and eczema. The Company in recent times presently commence Phase 2 clinical testing of PV-10 for melanoma and has received waif drug designation from the FDA for melanoma. Additionally, the Company has begin Phase 2 clinical testing of its topical service PH-10 for psoriasis. Complementing their suite of proprietary drugs, Provectus has programmed a trifling serious property and technology in the areas of medical devices and biotechnology. For optional reason something close to Provectus funniness call on the Company’s website at Forward-Looking Statements The forward-looking statement contained herein are premise to indubitable peril and uncertainties that could bring into being actual results to swerve materially from those echo in the forward-looking statements. Readers are give an opinion not to situation undue faith on these forward-looking statements, which reflect management’s analysis with the sole target starting the date hereof. The Company undertake no responsibility to publicly go through these forward-looking statements to reflect relations or environment that arise after the date thereof.